"Right to repair" legislation is an issue that political candidates across the U.S. have made part of their affordability ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association ...

A clinical trial to reverse age-related vision conditions using stem cell treatment could finally deliver on the promise of a ...

A new study by researchers at Fox Chase Cancer Center focusing on pancreatic cancer has shown that a new scoring system can ...

A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.

The stiffness of tumour tissue plays a role in how cancer spreads. Furthermore, stiff tumour tissue leaves traces in the ...

Researchers showed that an experimental therapy indirectly converted suppressive immune cells into tumor-fighting cells. This ...

In this excerpt from “We Are As Gods: A Survival God for the Age of Abundance,” authors Peter H. Diamandis and Steven Kotler ...

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...